Overview

A Study of Orelabrutinib in Patients With ITP

Status:
Not yet recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Peking University People's Hospital